Quarterly Net Profit at Rs. 91.30 crore in December 2024 down 33.7% from Rs. 137.70 crore in December 2023. EBITDA stands at ...

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

For the quarter, the S&P 500® Index added 2.41%, while the MSCI EAFE Index slid 8.11%. Click here to read the full commentary ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...